Last updated: October 15, 2026
Butorphanol tartrate is a mature, generic opioid with limited commercial growth potential. Human-market revenue is fragmented across injectable and nasal-spray products, while veterinary demand provides a separate, more durable outlet. The principal commercial constraints are generic price competition, controlled-substance compliance, limited clinical differentiation, and low visibility in public company reporting. No meaningful branded exclusivity remains for the historical Stadol franchise, and generic entry risk is high.
What is the current market position of butorphanol tartrate?
Butorphanol tartrate is a synthetic opioid analgesic with kappa-opioid receptor agonist activity and mu-opioid receptor antagonist or partial agonist activity. It is marketed in human and veterinary formulations.
| Market segment |
Principal use |
Typical formulation |
Commercial position |
| Human acute care |
Short-term treatment of pain, including postoperative pain |
Injectable solution |
Generic, hospital and institutional market |
| Human outpatient care |
Migraine treatment |
Nasal spray |
Generic, niche outpatient market |
| Veterinary medicine |
Analgesia, sedation and preanesthesia |
Injectable solution, tablets, compounded products |
Established specialty and companion-animal market |
| Research and specialty use |
Opioid pharmacology and controlled analgesia |
Various |
Small, non-core demand |
The historical branded product was Stadol, commercialized by Bristol-Myers Squibb. Stadol injection and Stadol NS lost commercial importance after generic products entered the market and the brand was discontinued or no longer broadly marketed in the United States. Current demand is supplied primarily through generic manufacturers, hospital distributors, veterinary suppliers and compounding channels.
Butorphanol is a Schedule IV controlled substance in the United States. That classification is less restrictive than Schedule II opioid products, but manufacturers and distributors still face quota, security, recordkeeping, suspicious-order monitoring and state-controlled-substance requirements under the Controlled Substances Act (U.S. Drug Enforcement Administration, n.d.).
How large is the butorphanol tartrate market?
A reliable global revenue figure for butorphanol tartrate is not available from public company disclosures. Manufacturers generally report the product within broader generic injectable, hospital, animal-health or specialty-pharmaceutical categories.
The market is best characterized as a low-revenue, mature pharmaceutical segment rather than a high-growth drug franchise. Its economic profile has four defining traits:
- Human products are largely generic and price-sensitive.
- Injectable demand is tied to hospitals, ambulatory surgery and institutional purchasing.
- Nasal-spray demand is smaller and exposed to migraine-treatment substitution.
- Veterinary sales are commercially important relative to human branded sales but are not usually disclosed as a separate financial line.
Public financial filings from large generic manufacturers do not generally identify butorphanol tartrate revenue separately. The product therefore has limited value as a standalone investment thesis. Its value is more likely to arise from portfolio breadth, manufacturing utilization, hospital contracting and veterinary distribution than from molecule-level pricing power.
What is the financial trajectory for butorphanol tartrate?
The financial trajectory is mature to declining in human branded terms, with stable or modestly growing demand in selected veterinary and institutional channels.
Human pharmaceutical outlook
Human injectable butorphanol remains relevant where clinicians require a parenteral opioid with mixed agonist-antagonist pharmacology. Its use is constrained by competition from morphine, hydromorphone, fentanyl, ketorolac, tramadol and other analgesic options. Hospitals also maintain opioid formularies that prioritize products with greater purchasing scale or more established clinical protocols.
The nasal spray has a narrower commercial base. It may be used for acute migraine treatment, but it competes with triptans, gepants, dihydroergotamine products, nonsteroidal anti-inflammatory drugs and newer migraine therapies. The nasal route provides a delivery advantage for patients who cannot tolerate oral medication, but butorphanol's opioid-related safety and dependence concerns restrict broad adoption.
Human revenue is therefore likely to remain concentrated in:
- Generic institutional contracts
- Emergency and perioperative use
- Limited outpatient nasal-spray prescriptions
- Regional supply arrangements
- Products included in broad injectable portfolios
Veterinary outlook
Veterinary use creates a more durable demand base. Butorphanol is used in dogs, cats, horses and other animals for analgesia, sedation, preanesthetic medication and cough suppression in selected products. Veterinary demand benefits from continued procedural care and companion-animal medicine, but pricing remains constrained by competition from buprenorphine, dexmedetomidine, nonsteroidal anti-inflammatory drugs and other sedative or analgesic products.
The veterinary market has stronger product differentiation than the human generic market because formulation, species labeling, distribution access and clinician familiarity influence purchasing decisions. The economic value of a veterinary butorphanol product can therefore exceed the value suggested by its active ingredient alone.
What FDA products contain butorphanol tartrate?
FDA-regulated human products have historically included injectable and nasal-spray dosage forms.
| Dosage form |
Regulatory pathway or product type |
Primary commercial channel |
| Injection |
NDA-originated and ANDA generic products |
Hospitals, clinics and surgery centers |
| Nasal spray |
NDA-originated and ANDA generic products |
Retail, specialty and outpatient channels |
| Veterinary injection |
Animal-drug approval pathway |
Veterinary hospitals and distributors |
| Veterinary oral products |
Veterinary product approvals or compounded preparations |
Veterinary practices and pharmacies |
The FDA labeling for butorphanol tartrate injection identifies use for the management of pain when an opioid analgesic is appropriate. The labeling also addresses respiratory depression, dependence, withdrawal, sedation and interaction risks (U.S. Food and Drug Administration, n.d.-a).
The nasal-spray labeling identifies acute migraine treatment in adults. The product is not positioned as a chronic pain medicine, and labeling restrictions limit the opportunity to expand use into long-term analgesia (U.S. Food and Drug Administration, n.d.-b).
What is the Orange Book status of butorphanol tartrate?
Butorphanol tartrate has no commercially significant remaining period of new-drug exclusivity associated with the original Stadol products. The core composition-of-matter and original product protections expired long ago, allowing multiple generic products to enter the market.
The relevant Orange Book issues are now practical rather than strategic:
- Whether a specific product remains listed as actively marketed
- Whether the product has any listed patents or exclusivity
- Whether an ANDA sponsor has an approved product for the same route and strength
- Whether a manufacturer has discontinued a presentation
- Whether an injectable or nasal-spray product is subject to a supply interruption
For a mature product such as butorphanol, Orange Book status does not by itself determine commercial availability. A product may remain approved while having limited distribution, no active commercial supply or intermittent manufacturing.
What patents protect butorphanol tartrate?
The original butorphanol molecule and the principal human dosage forms are not protected by a meaningful active patent estate in the United States. The historic patent position centered on the active compound, pharmaceutical compositions and early formulations. Those rights are expired.
Formulation patents
Any remaining formulation or device-related rights would need to be evaluated at the product level. Potential claim categories include:
- Nasal-spray delivery devices
- Metered-dose mechanisms
- Preservative systems
- Spray stability and particle-size control
- Injectable compositions
- Container-closure systems
- Manufacturing processes
These categories do not create a known broad barrier to generic competition for the established products. A later formulation patent would have commercial value only if it covered a differentiated product with an approved label, reliable supply and meaningful clinical or operational advantages.
Method-of-use patents
The broad historical uses of butorphanol for pain and migraine treatment are old and generally vulnerable to generic competition. Method-of-use patents, if any remain relevant for a particular product, would not prevent approval of a generic for nonprotected indications if the FDA permits a section viii or other appropriate label carve-out.
When does butorphanol tartrate lose exclusivity?
Butorphanol tartrate lost practical market exclusivity years ago. The original Stadol franchise is a legacy product, and generic entry has already occurred for human injection and nasal spray products.
The applicable exclusivity framework is therefore:
| Exclusivity type |
Current commercial impact |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not a central feature of the product |
| Pediatric exclusivity |
No material current barrier identified |
| Original formulation protection |
Expired or commercially immaterial |
| Generic competition |
Established |
| Veterinary market protection |
Product-specific and separate from human exclusivity |
Which companies manufacture or distribute butorphanol tartrate?
Human generic manufacturers and suppliers have included companies active in injectable and specialty generic pharmaceuticals, such as Hikma Pharmaceuticals, Fresenius Kabi, Dr. Reddy's Laboratories, Akorn historically, and other ANDA holders depending on the presentation and market period. Product availability changes as companies discontinue low-volume products, transfer approvals or consolidate manufacturing.
Veterinary suppliers have included animal-health companies such as Zoetis and other approved veterinary manufacturers. The competitive set differs between human and veterinary markets because approval pathways, distribution networks, species labeling and controlled-substance handling requirements are distinct.
Company-level exposure is difficult to quantify because butorphanol is normally bundled into broader revenue categories. A manufacturer with a hospital generic portfolio may treat the product as a supply-completion item rather than a material revenue contributor.
Are there Paragraph IV challenges involving butorphanol tartrate?
Paragraph IV litigation is not a significant current market driver for butorphanol tartrate. The product's main patents are old, generic entry has already taken place, and no prominent active patent dispute is associated with the historical human products.
For a new nasal device, extended-release formulation or other differentiated product, a Paragraph IV challenge could arise if the sponsor listed an Orange Book patent. That scenario would concern the new formulation rather than the ordinary generic injectable or conventional nasal spray.
The practical generic-entry risk is therefore not litigation delay. It is supply economics. Low-volume products can attract few suppliers, and shortages may occur even when no patent prevents production.
What patent litigation and settlement agreements affect butorphanol?
No major current patent settlement agreement materially restricts generic competition for standard butorphanol tartrate products. The historical litigation environment is less important than:
- FDA approval status
- Manufacturing-site compliance
- Controlled-substance quotas
- Hospital contracting
- Raw-material availability
- Product profitability
- Distribution continuity
A settlement would have limited economic value unless it involved a newly patented delivery system or a commercially differentiated product.
How strong is the butorphanol tartrate patent estate?
The patent estate is weak for standard products and potentially moderate only for a new delivery platform.
| Estate component |
Strength |
Commercial implication |
| Active ingredient |
Low |
No practical exclusivity |
| Standard injection |
Low |
Generic substitution is established |
| Conventional nasal spray |
Low |
Price and supply determine competition |
| Novel nasal device |
Product-specific |
Could support limited differentiation |
| New indication |
Low to moderate |
Depends on enforceable claims and label strategy |
| Manufacturing process |
Low to moderate |
May protect know-how more than market access |
The most defensible barriers are likely regulatory and operational rather than patent-based. Controlled-substance compliance, validated sterile manufacturing, device production and reliable distribution can deter smaller entrants without creating legally enforceable market exclusivity.
What generic launch scenarios exist for butorphanol tartrate?
Three scenarios define future competition.
Continued multi-source supply
Several manufacturers remain active, hospital buyers retain alternatives, and prices stay low. This is the base case for mature injectable products.
Supplier contraction
One or more manufacturers discontinue a low-volume presentation. Remaining suppliers gain temporary negotiating leverage, but the market does not become structurally protected. Shortage risk rises because replacement manufacturing requires FDA approval, controlled-substance quota allocation and validated sterile capacity.
New delivery-system entry
A company introduces a differentiated nasal, injectable or veterinary product. Commercial success depends on clinical utility, reimbursement, distribution and device reliability. A new patent estate could delay direct substitution, but the addressable market remains limited.
What is the competitive landscape compared with other opioids?
Butorphanol has a differentiated pharmacologic profile but limited market power.
| Product |
Relative strength versus butorphanol |
| Fentanyl |
Stronger institutional demand and broader procedural use |
| Morphine |
Greater formulary penetration and lower historical cost |
| Hydromorphone |
Strong hospital presence for severe pain |
| Buprenorphine |
Strong veterinary and specialty positioning |
| Tramadol |
Broader outpatient use in several markets |
| Ketorolac |
Non-opioid alternative for selected acute pain |
| Gepants and triptans |
Stronger migraine-specific positioning than opioid nasal spray |
Butorphanol can compete where its mixed agonist-antagonist profile, route of administration or veterinary label provides a specific advantage. It does not compete effectively on brand strength, patent protection or broad market growth.
What regulatory risks affect butorphanol tartrate?
The main regulatory risks are product quality, controlled-substance compliance and safety surveillance.
FDA and state regulators can impose commercial pressure through:
- Manufacturing observations or warning letters
- Injectable sterility and particulate concerns
- Nasal-spray dose-delivery variability
- Opioid labeling requirements
- Controlled-substance recordkeeping violations
- Distribution restrictions
- Product recalls or shortages
Safety concerns include respiratory depression, sedation, misuse, dependence, withdrawal and interactions with other central nervous system depressants. The product's Schedule IV status reduces some barriers compared with Schedule II opioids but does not eliminate compliance costs.
What is the revenue exposure for pharmaceutical companies?
Butorphanol is unlikely to represent material revenue exposure for a diversified pharmaceutical company unless the company specializes in hospital generics, veterinary pharmaceuticals or niche controlled substances.
Revenue sensitivity is driven by:
- Number of approved competitors
- Contract concentration
- Product discontinuations
- Hospital purchasing cycles
- Veterinary clinic utilization
- Active manufacturing sites
- Supply shortages
- Raw-material and sterile-fill costs
A company with one of few active injectable suppliers may generate disproportionate value from continuity of supply. That value is usually temporary and operational, not protected by patents.
Key Takeaways
- Butorphanol tartrate is a mature generic opioid with human and veterinary markets.
- The original Stadol franchise has no meaningful remaining branded exclusivity.
- Standard injection and nasal-spray products face high generic-entry risk.
- Public companies generally do not disclose butorphanol revenue separately.
- Veterinary products provide a more durable commercial niche than human branded products.
- The principal barriers are sterile manufacturing, controlled-substance compliance and distribution, not patents.
- Paragraph IV litigation and patent settlements are not major current market drivers.
- Financial upside is limited unless linked to a supply shortage, a differentiated delivery system or a specialized veterinary platform.
- The human market is likely stable to declining in value, while veterinary demand is more resilient.
- Product-level FDA approval, active marketing and supply status matter more than the historical patent estate.
FAQs About Butorphanol Tartrate Market and Exclusivity
Is butorphanol tartrate still commercially available?
Yes. Availability depends on the dosage form, manufacturer, country and distribution channel. Human injectable and nasal-spray products may have different supplier and shortage profiles.
Is butorphanol tartrate a generic drug?
Yes. Human butorphanol tartrate products are generally marketed as generic products, while veterinary products may be sold under branded animal-health labels or as compounded preparations.
Can a new company obtain patent protection for butorphanol tartrate?
A new company may obtain patents for a novel formulation, delivery device, manufacturing process or method of use if the claims satisfy patentability requirements. It cannot ordinarily revive broad exclusivity for the old active ingredient.
Does butorphanol compete with buprenorphine in veterinary medicine?
Yes. Both are used in veterinary analgesia and sedation, although their pharmacology, species labeling, duration, handling requirements and clinical roles differ.
Is butorphanol tartrate attractive for pharmaceutical licensing?
The standard generic product has limited licensing value. A transaction could be more attractive for a differentiated nasal device, veterinary formulation, reliable sterile supply platform or product with an enforceable patent and regulatory advantage.
References
-
U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
-
U.S. Food and Drug Administration. (n.d.-a). Butorphanol tartrate injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Butorphanol tartrate nasal spray prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-d). FDA drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
-
U.S. Food and Drug Administration. (n.d.-e). Generic drug approvals and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.-f). Approved animal drug products. https://animaldrugsatfda.fda.gov/adafda/views/###
